Company news
Dyne Therapeutics, Inc. news in 2021
Dyne Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.
Dyne Therapeutics Announces Submission of IND Application to Initiate Clinical Trial of DYNE-251 for Duchenne Muscular Dystrophy
December 1, 2021
Dyne Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
November 3, 2021
Dyne Therapeutics Highlights Preclinical Data and Clinical Development Plans for DMD and DM1 Programs at Inaugural R&D Day
October 12, 2021
Dyne Therapeutics Presents New In Vivo Data for its Duchenne Muscular Dystrophy Program During Muscle Study Group Annual Scientific Meeting Demonstrating Robust and Durable Exon Skipping and Dystrophin Expression
September 30, 2021
Dyne Therapeutics to Host Virtual Research and Development Day on Wednesday, October 13, 2021
September 27, 2021
Dyne Therapeutics to Present at Chardan’s Virtual 5th Annual Genetic Medicines Conference
September 26, 2021
Dyne Therapeutics Presents New In Vivo Data for its Myotonic Dystrophy Type 1 Candidate (DYNE-101) Demonstrating Robust Splicing Correction During World Muscle Society 2021 Virtual Congress
September 19, 2021
Dyne Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights
August 4, 2021
Dyne Therapeutics Presents Preclinical Data from its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
June 24, 2021
Dyne Therapeutics Announces Chief Scientific Officer Transition
June 1, 2021
Dyne Therapeutics to Present at Jefferies Virtual Healthcare Conference
May 25, 2021
Dyne Therapeutics Presents New Preclinical Data from its Myotonic Dystrophy Type 1 Program During American Society of Gene & Cell Therapy Annual Meeting Demonstrating Sustained Knockdown of Toxic Human Nuclear DMPK RNA
May 13, 2021
Dyne Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights
May 5, 2021
New Preclinical Data from Dyne Therapeutics’ Myotonic Dystrophy Type 1 Program to be Featured in Presentations During Upcoming American Society of Gene & Cell Therapy Annual Meeting
April 26, 2021
Dyne Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights
March 3, 2021
Dyne Therapeutics Appoints Wildon Farwell, M.D., MPH, as Chief Medical Officer
March 3, 2021
Dyne Therapeutics Appoints Ashish Dugar, Ph.D., MBA, Senior Vice President, Global Head of Medical Affairs
February 7, 2021
Dyne Therapeutics Announces Pricing of $168 Million Public Offering
January 19, 2021
Dyne Therapeutics Myotonic Dystrophy Type 1 Program Achieves Robust RNA Knock Down of Toxic Human Nuclear DMPK in Preclinical Study
January 9, 2021
Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
January 4, 2021
Decks in 2021
- Muscle Study Group Annual Scientific Meeting 2021
Conference · 29 slides · Nov 4, 2021
- FSHD IRC 2021
Conference · 11 slides · Jun 25, 2021
- ASGCT Annual Meeting 2021
Conference · 19 slides · May 14, 2021